Browse BRAF

Summary
SymbolBRAF
NameB-Raf proto-oncogene, serine/threonine kinase
Aliases BRAF1; v-raf murine sarcoma viral oncogene homolog B; B-RAF11; NS7; RAFB1; 94 kDa B-raf protein; B-Raf proto ......
Chromosomal Location7q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Cytoplasm. Cell membrane Note=Colocalizes with RGS14 and RAF1 in both the cytoplasm and membranes.
Domain PF00130 Phorbol esters/diacylglycerol binding domain (C1 domain)
PF07714 Protein tyrosine kinase
PF02196 Raf-like Ras-binding domain
Function

Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron. Phosphorylates MAP2K1, and thereby contributes to the MAP kinase signal transduction pathway.

> Gene Ontology
 
Biological Process GO:0000186 activation of MAPKK activity
GO:0001505 regulation of neurotransmitter levels
GO:0001667 ameboidal-type cell migration
GO:0002244 hematopoietic progenitor cell differentiation
GO:0002318 myeloid progenitor cell differentiation
GO:0002521 leukocyte differentiation
GO:0006836 neurotransmitter transport
GO:0006887 exocytosis
GO:0007015 actin filament organization
GO:0007159 leukocyte cell-cell adhesion
GO:0007269 neurotransmitter secretion
GO:0007409 axonogenesis
GO:0007611 learning or memory
GO:0007612 learning
GO:0007632 visual behavior
GO:0008306 associative learning
GO:0008542 visual learning
GO:0008643 carbohydrate transport
GO:0008645 hexose transport
GO:0009314 response to radiation
GO:0009416 response to light stimulus
GO:0010035 response to inorganic substance
GO:0010038 response to metal ion
GO:0010171 body morphogenesis
GO:0010720 positive regulation of cell development
GO:0010761 fibroblast migration
GO:0010762 regulation of fibroblast migration
GO:0010764 negative regulation of fibroblast migration
GO:0010769 regulation of cell morphogenesis involved in differentiation
GO:0010770 positive regulation of cell morphogenesis involved in differentiation
GO:0010810 regulation of cell-substrate adhesion
GO:0010811 positive regulation of cell-substrate adhesion
GO:0010975 regulation of neuron projection development
GO:0010976 positive regulation of neuron projection development
GO:0014074 response to purine-containing compound
GO:0015749 monosaccharide transport
GO:0015758 glucose transport
GO:0016079 synaptic vesicle exocytosis
GO:0017156 calcium ion regulated exocytosis
GO:0017157 regulation of exocytosis
GO:0017158 regulation of calcium ion-dependent exocytosis
GO:0018105 peptidyl-serine phosphorylation
GO:0018209 peptidyl-serine modification
GO:0019827 stem cell population maintenance
GO:0022604 regulation of cell morphogenesis
GO:0023061 signal release
GO:0030038 contractile actin filament bundle assembly
GO:0030098 lymphocyte differentiation
GO:0030217 T cell differentiation
GO:0030336 negative regulation of cell migration
GO:0030878 thyroid gland development
GO:0031032 actomyosin structure organization
GO:0031099 regeneration
GO:0031102 neuron projection regeneration
GO:0031103 axon regeneration
GO:0031346 positive regulation of cell projection organization
GO:0031589 cell-substrate adhesion
GO:0032103 positive regulation of response to external stimulus
GO:0032147 activation of protein kinase activity
GO:0032231 regulation of actin filament bundle assembly
GO:0032233 positive regulation of actin filament bundle assembly
GO:0032956 regulation of actin cytoskeleton organization
GO:0032970 regulation of actin filament-based process
GO:0033135 regulation of peptidyl-serine phosphorylation
GO:0033138 positive regulation of peptidyl-serine phosphorylation
GO:0033674 positive regulation of kinase activity
GO:0034446 substrate adhesion-dependent cell spreading
GO:0035019 somatic stem cell population maintenance
GO:0035270 endocrine system development
GO:0035690 cellular response to drug
GO:0035710 CD4-positive, alpha-beta T cell activation
GO:0040013 negative regulation of locomotion
GO:0042110 T cell activation
GO:0042493 response to drug
GO:0043149 stress fiber assembly
GO:0043367 CD4-positive, alpha-beta T cell differentiation
GO:0043368 positive T cell selection
GO:0043405 regulation of MAP kinase activity
GO:0043410 positive regulation of MAPK cascade
GO:0043434 response to peptide hormone
GO:0043523 regulation of neuron apoptotic process
GO:0043524 negative regulation of neuron apoptotic process
GO:0044089 positive regulation of cellular component biogenesis
GO:0044708 single-organism behavior
GO:0045055 regulated exocytosis
GO:0045058 T cell selection
GO:0045666 positive regulation of neuron differentiation
GO:0045785 positive regulation of cell adhesion
GO:0045860 positive regulation of protein kinase activity
GO:0045920 negative regulation of exocytosis
GO:0045955 negative regulation of calcium ion-dependent exocytosis
GO:0046631 alpha-beta T cell activation
GO:0046632 alpha-beta T cell differentiation
GO:0046683 response to organophosphorus
GO:0046928 regulation of neurotransmitter secretion
GO:0046929 negative regulation of neurotransmitter secretion
GO:0048167 regulation of synaptic plasticity
GO:0048489 synaptic vesicle transport
GO:0048538 thymus development
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048678 response to axon injury
GO:0048679 regulation of axon regeneration
GO:0048680 positive regulation of axon regeneration
GO:0048732 gland development
GO:0050769 positive regulation of neurogenesis
GO:0050770 regulation of axonogenesis
GO:0050772 positive regulation of axonogenesis
GO:0050804 modulation of synaptic transmission
GO:0050805 negative regulation of synaptic transmission
GO:0050806 positive regulation of synaptic transmission
GO:0050890 cognition
GO:0051017 actin filament bundle assembly
GO:0051048 negative regulation of secretion
GO:0051051 negative regulation of transport
GO:0051259 protein oligomerization
GO:0051271 negative regulation of cellular component movement
GO:0051291 protein heterooligomerization
GO:0051402 neuron apoptotic process
GO:0051492 regulation of stress fiber assembly
GO:0051493 regulation of cytoskeleton organization
GO:0051495 positive regulation of cytoskeleton organization
GO:0051496 positive regulation of stress fiber assembly
GO:0051588 regulation of neurotransmitter transport
GO:0051589 negative regulation of neurotransmitter transport
GO:0051591 response to cAMP
GO:0051592 response to calcium ion
GO:0051640 organelle localization
GO:0051648 vesicle localization
GO:0051650 establishment of vesicle localization
GO:0051656 establishment of organelle localization
GO:0051962 positive regulation of nervous system development
GO:0060291 long-term synaptic potentiation
GO:0060323 head morphogenesis
GO:0060324 face development
GO:0060627 regulation of vesicle-mediated transport
GO:0061564 axon development
GO:0061572 actin filament bundle organization
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070570 regulation of neuron projection regeneration
GO:0070572 positive regulation of neuron projection regeneration
GO:0070997 neuron death
GO:0071241 cellular response to inorganic substance
GO:0071248 cellular response to metal ion
GO:0071277 cellular response to calcium ion
GO:0071593 lymphocyte aggregation
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0072577 endothelial cell apoptotic process
GO:0072657 protein localization to membrane
GO:0090150 establishment of protein localization to membrane
GO:0097479 synaptic vesicle localization
GO:0097480 establishment of synaptic vesicle localization
GO:0098727 maintenance of cell number
GO:0099003 vesicle-mediated transport in synapse
GO:0099504 synaptic vesicle cycle
GO:0099531 presynaptic process involved in chemical synaptic transmission
GO:0099643 signal release from synapse
GO:1900024 regulation of substrate adhesion-dependent cell spreading
GO:1900026 positive regulation of substrate adhesion-dependent cell spreading
GO:1901214 regulation of neuron death
GO:1901215 negative regulation of neuron death
GO:1901652 response to peptide
GO:1902803 regulation of synaptic vesicle transport
GO:1902804 negative regulation of synaptic vesicle transport
GO:1903034 regulation of response to wounding
GO:1903036 positive regulation of response to wounding
GO:1903305 regulation of regulated secretory pathway
GO:1903306 negative regulation of regulated secretory pathway
GO:1903531 negative regulation of secretion by cell
GO:1904019 epithelial cell apoptotic process
GO:1904035 regulation of epithelial cell apoptotic process
GO:1904036 negative regulation of epithelial cell apoptotic process
GO:2000146 negative regulation of cell motility
GO:2000300 regulation of synaptic vesicle exocytosis
GO:2000301 negative regulation of synaptic vesicle exocytosis
GO:2000351 regulation of endothelial cell apoptotic process
GO:2000352 negative regulation of endothelial cell apoptotic process
Molecular Function GO:0004674 protein serine/threonine kinase activity
GO:0004702 receptor signaling protein serine/threonine kinase activity
GO:0004709 MAP kinase kinase kinase activity
GO:0005057 receptor signaling protein activity
GO:0031434 mitogen-activated protein kinase kinase binding
GO:0046982 protein heterodimerization activity
Cellular Component GO:0044297 cell body
> KEGG and Reactome Pathway
 
KEGG hsa04010 MAPK signaling pathway
hsa04012 ErbB signaling pathway
hsa04015 Rap1 signaling pathway
hsa04024 cAMP signaling pathway
hsa04062 Chemokine signaling pathway
hsa04068 FoxO signaling pathway
hsa04150 mTOR signaling pathway
hsa04270 Vascular smooth muscle contraction
hsa04320 Dorso-ventral axis formation
hsa04510 Focal adhesion
hsa04650 Natural killer cell mediated cytotoxicity
hsa04720 Long-term potentiation
hsa04722 Neurotrophin signaling pathway
hsa04726 Serotonergic synapse
hsa04730 Long-term depression
hsa04810 Regulation of actin cytoskeleton
hsa04910 Insulin signaling pathway
hsa04914 Progesterone-mediated oocyte maturation
Reactome R-HSA-170984: ARMS-mediated activation
R-HSA-442755: Activation of NMDA receptor upon glutamate binding and postsynaptic events
R-HSA-422475: Axon guidance
R-HSA-442742: CREB phosphorylation through the activation of Ras
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-186763: Downstream signal transduction
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-170968: Frs2-mediated activation
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-5674135: MAP2K and MAPK activation
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-5674499: Negative feedback regulation of MAPK pathway
R-HSA-5654726: Negative regulation of FGFR1 signaling
R-HSA-5654727: Negative regulation of FGFR2 signaling
R-HSA-5654732: Negative regulation of FGFR3 signaling
R-HSA-5654733: Negative regulation of FGFR4 signaling
R-HSA-5675221: Negative regulation of MAPK pathway
R-HSA-112316: Neuronal System
R-HSA-112314: Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
R-HSA-6802957: Oncogenic MAPK signaling
R-HSA-6802955: Paradoxical activation of RAF signaling by kinase inactive BRAF
R-HSA-438064: Post NMDA receptor activation events
R-HSA-169893: Prolonged ERK activation events
R-HSA-5673000: RAF activation
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-162582: Signal Transduction
R-HSA-6802952: Signaling by BRAF and RAF fusions
R-HSA-177929: Signaling by EGFR
R-HSA-190236: Signaling by FGFR
R-HSA-5654736: Signaling by FGFR1
R-HSA-5654738: Signaling by FGFR2
R-HSA-5654741: Signaling by FGFR3
R-HSA-5654743: Signaling by FGFR4
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-186797: Signaling by PDGF
R-HSA-6802949: Signaling by RAS mutants
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-6802948: Signaling by high-kinase activity BRAF mutants
R-HSA-6802946: Signaling by moderate kinase activity BRAF mutants
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-1295596: Spry regulation of FGF signaling
R-HSA-112315: Transmission across Chemical Synapses
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation
Summary
SymbolBRAF
NameB-Raf proto-oncogene, serine/threonine kinase
Aliases BRAF1; v-raf murine sarcoma viral oncogene homolog B; B-RAF11; NS7; RAFB1; 94 kDa B-raf protein; B-Raf proto ......
Chromosomal Location7q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between BRAF and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between BRAF and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26707829MelanomaResistant to immunotherapyThe greatest survival improvement was observed with the combination of BRAF plus MEK inhibitors as well as with Programmed-death-1 (PD1) blockers with or without cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blockers, respectively, with these two treatment strategies showing similar survival outcomes.
26343581MelanomaInhibit immunityGenetic ablation of cyclooxygenases (COX) or prostaglandin E synthases in Braf(V600E) mouse melanoma cells, as well as in Nras(G12D) melanoma or in breast or colorectal cancer cells, renders them susceptible to immune control and provokes a shift in the tumor inflammatory profile toward classic anti-cancer immune pathways.
25795007MelanomaInhibit immunity (T cell function)Collectively, these data suggest that oncogenic activation of BRAF allows tumor cells to co-opt an evolutionarily conserved MHC-I trafficking pathway as a strategy to facilitate immune evasion.
25787767MelanomaInhibit immunity (T cell function)Our findings support the testing of triple combination therapy of BRAF and MEK inhibitors with immunotherapy in patients with BRAF(V600E) mutant metastatic melanoma.
22693252MelanomaInhibit immunityBRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.
29370526MelanomaInhibit immunity (infiltration); Resistant to immunotherapyNanoparticle-Mediated Trapping of Wnt Family Member 5A in Tumor Microenvironments Enhances Immunotherapy for B-Raf Proto-Oncogene Mutant Melanoma. Approximately 50% of human melanoma is driven by B-Raf proto-oncogene mutation (BRAF mutant). Tumors with such mutation are desmoplastic, highly immunosuppressive, and often resistant to immune checkpoint therapies. Wnt family member 5A (Wnt5a), a signaling protein highly produced by BRAF mutant melanoma cells, has been implicated in inducing dendritic cell tolerance and tumor fibrosis, thus hindering effective antigen presentation and T-cell infiltration.
24577748MelanomaResistant to immunotherapyOutcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.
24489105MelanomaInhibit immunityDynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment. These results suggest that BRAF inhibition causes decreased CXCL8 secretion from melanoma cells and induce an immune response against the tumor associated with increased IFN-γ, CCL4, and TNF-α. The decrease in serum CXCL8 levels from PRE to EDT significantly correlated with decreases in markers of melanoma proliferation (Ki-67) and increases in cytotoxic tumor-infiltrating T cells in corresponding tumor biopsies.
23204132MelanomaInhibit immunityThese findings provide a strong rationale to evaluate the potential clinical application of combining BRAF inhibition with T-cell-based immunotherapy for the treatment of patients with melanoma. Furthermore, analysis of human melanoma patient tumor biopsies before and during BRAF inhibitor treatment showed downregulation of VEGF consistent with the preclinical murine model.
18008004MelanomaInhibit immunity (T cell function)Employing 2 independent, genome-wide microarray analyses, we identified CD200 as a highly dynamic, downstream target of RAS/RAF/MEK/ERK activation in melanoma. CD200 protein was similarly overexpressed in human melanoma cell lines and primary tumors. Melanoma cell lines expressing endogenous CD200 repressed primary T cell activation by DCs, while knockdown of CD200 by shRNA abrogated this immunosuppressive effect.
24958825melanomaResistant to immunotherapyTargeted therapy can successfully block oncogenic signaling in BRAF(V600)-mutant melanoma with high initial clinical responses, but relapse rates are also high.
29573941melanomaInhibit immunityWe investigated encorafenib, a BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK inhibitor binimetinib, versus vemurafenib in patients with advanced BRAFV600-mutant melanoma.
29483645MelanomaResistant to immunotherapyWe also found that oncogenic BRAF positively regulates expression, phosphorylation, and nuclear localization of ERK5.
22850568MelanomaInhibit immunityExpression of BRAF(V600E) induced transcription of interleukin 1 alpha (IL-1α) and IL-1β in melanocytes and melanoma cell lines. Treatment of melanoma-patient-derived TAFs with IL-1α/β significantly enhanced their ability to suppress the proliferation and function of melanoma-specific cytotoxic T cells, and this inhibition was partially attributable to upregulation by IL-1 of COX-2 and the PD-1 ligands PD-L1 and PD-L2 in TAFs.
22156613MelanomaInhibit immunity (infiltration)Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Tumor infiltration by CD4(+) and CD8(+) lymphocytes increased markedly following BRAF inhibitor treatment (both ρ = 0.015).
20551059MelanomaInhibit immunityWe show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor digests results in increased levels of MDAs, which is associated with improved recognition by antigen-specific T lymphocytes. These findings suggest that immune evasion of melanomas mediated by oncogenic BRAF may be reversed by targeted BRAF inhibition without compromising T-cell function.
25183499melanomaInhibit immunityThese findings demonstrate that BRAF inhibition selectively reverses two major mechanisms of immunosuppression in melanoma and liberates host-adaptive antitumor immunity
25178978melanomaInhibit immunityThe discovery that BRAF is a driver oncogene in cancer, and complementary improvements in our understanding of the immune system have resulted in new targeted and immune-therapies for metastatic melanoma
25174651melanomaInhibit immunityBRAF mutation-related specific transcripts associate with the poor melanoma phenotype and such association resulted particularly strong in BRAF mutant tumors displaying low expression levels of this gene
23307859MelanomaInhibit immunityTogether, these data suggest that treatment with BRAF inhibition enhances melanoma antigen expression and facilitates T-cell cytotoxicity and a more favorable tumor microenvironment, providing support for potential synergy of BRAF-targeted therapy and immunotherapy.
23251000MelanomaInhibit immunityCombining the BRAF inhibitors with immunotherapy may prolong the response, but will acquisition of resistance to BRAF inhibitors also make melanoma cells resistant to immunotherapy
Summary
SymbolBRAF
NameB-Raf proto-oncogene, serine/threonine kinase
Aliases BRAF1; v-raf murine sarcoma viral oncogene homolog B; B-RAF11; NS7; RAFB1; 94 kDa B-raf protein; B-Raf proto ......
Chromosomal Location7q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of BRAF in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.65 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolBRAF
NameB-Raf proto-oncogene, serine/threonine kinase
Aliases BRAF1; v-raf murine sarcoma viral oncogene homolog B; B-RAF11; NS7; RAFB1; 94 kDa B-raf protein; B-Raf proto ......
Chromosomal Location7q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of BRAF in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.270.408
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.9340.355
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2140.779
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0350.917
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0520.983
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1410.963
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0970.735
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0590.955
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1850.868
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0980.915
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4640.717
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0010.993
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of BRAF in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277344.435.68.80.489
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 014085.7-85.71
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275944.423.720.70.076
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211752.452.9-0.51
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8662.55012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131146.254.5-8.31
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382723.740.7-170.177
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221318.238.5-20.30.243
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161431.242.9-11.70.707
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolBRAF
NameB-Raf proto-oncogene, serine/threonine kinase
Aliases BRAF1; v-raf murine sarcoma viral oncogene homolog B; B-RAF11; NS7; RAFB1; 94 kDa B-raf protein; B-Raf proto ......
Chromosomal Location7q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of BRAF. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolBRAF
NameB-Raf proto-oncogene, serine/threonine kinase
Aliases BRAF1; v-raf murine sarcoma viral oncogene homolog B; B-RAF11; NS7; RAFB1; 94 kDa B-raf protein; B-Raf proto ......
Chromosomal Location7q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of BRAF. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by BRAF.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolBRAF
NameB-Raf proto-oncogene, serine/threonine kinase
Aliases BRAF1; v-raf murine sarcoma viral oncogene homolog B; B-RAF11; NS7; RAFB1; 94 kDa B-raf protein; B-Raf proto ......
Chromosomal Location7q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of BRAF. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolBRAF
NameB-Raf proto-oncogene, serine/threonine kinase
Aliases BRAF1; v-raf murine sarcoma viral oncogene homolog B; B-RAF11; NS7; RAFB1; 94 kDa B-raf protein; B-Raf proto ......
Chromosomal Location7q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of BRAF expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolBRAF
NameB-Raf proto-oncogene, serine/threonine kinase
Aliases BRAF1; v-raf murine sarcoma viral oncogene homolog B; B-RAF11; NS7; RAFB1; 94 kDa B-raf protein; B-Raf proto ......
Chromosomal Location7q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between BRAF and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolBRAF
NameB-Raf proto-oncogene, serine/threonine kinase
Aliases BRAF1; v-raf murine sarcoma viral oncogene homolog B; B-RAF11; NS7; RAFB1; 94 kDa B-raf protein; B-Raf proto ......
Chromosomal Location7q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting BRAF collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting BRAF.
ID Name Drug Type Targets #Targets
DB00398SorafenibSmall MoleculeBRAF, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET10
DB05190XL281Small MoleculeBRAF, RAF12
DB05984RAF-265Small MoleculeBRAF, KDR2
DB06999N-{3-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]-2,4-difluorophenyl}propane-1-sulfonamideSmall MoleculeBRAF1
DB07000N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamideSmall MoleculeBRAF1
DB08553(1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oximeSmall MoleculeBRAF1
DB08881VemurafenibSmall MoleculeBRAF1
DB08896RegorafenibSmall MoleculeABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, ......18
DB08912DabrafenibSmall MoleculeBRAF, LIMK1, NEK11, RAF1, SIK15